Pharmaceuticals company Jagsonpal Pharmaceuticals announced Q1FY26 results Revenue stood at Rs 756 million, up 23.1% year-on-year Operating EBITDA came in at Rs 157 million, rising 24.1% YoY EBITDA margin was 20.8%, expanding by 17 bps YoY ESOP cost was Rs 15 million, down 38.9% from Q1FY25 PAT stood at Rs 108 million, with a margin expansion of 562 bps YoY Commenting on the performance for the quarter, Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals said, “We have started FY 26 on a strong note with growth across all parameters. While our Revenue grew 23.1% to Rs 756 million, operating EBITDA was at Rs 157 million, up by 24.1%. The continued scale up is an outcome of our disciplined and effective execution of our strategy. Net profit for the quarter more than doubled to Rs 108 million, with addition of another Rs 153 million of free cash, which stood at Rs 1609 million as on 30th June 2025. We further strengthened our position to #7 in the Gynae CVM rankings, reinforcing our leadership in the category. We expect the growth momentum to continue as we deepen our presence in the domestic pharmaceutical market coupled with prudent use of free cash to look for a strategically suitable inorganic opportunity.“ Result PDF
Conference Call with Jagsonpal Pharmaceuticals Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Jagsonpal Pharmaceuticals announced Q4FY25 results Revenue: Rs 586 million compared to Rs 435 million during Q4FY24, change 34.7%. EBITDA: Rs 97 million compared to Rs 49 million during Q4FY24, change 96.6%. EBITDA margin: 16.6% for Q4FY25. PAT: Rs 66 million compared to Rs 35 million during Q4FY24, change 85.5%. Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals, said: “We are pleased with our FY25 performance, which underscores the strength of our strategy and execution. Revenue grew 29% to Rs 2,687 million, while operating EBITDA rose 59% to Rs 579 million, driven by a 410 bps margin expansion—reflecting disciplined cost management and successful business integration. Our strategic initiatives are delivering results across key metrics. A major milestone was Indocap® becoming Jagsonpal’s first Rs 50 crore brand (Source: IQVIA), highlighting its strong brand equity. The launch of Indocap® P to further strengthen our leadership in safer pain management. Our Q4FY25 results reaffirm operational alignment, with revenue of Rs586 million (up 35%) and operating EBITDA of Rs 97 million (up 97%). Our key focus now remains on accelerating organic growth even as we continue to evaluate synergistic inorganic opportunities. With strong internal accruals and a healthy balance sheet, we are well-positioned to invest for long-term value creation.” Result PDF
Pharmaceuticals company Jagsonpal Pharmaceuticals announced Q3FY25 results Revenue: Rs 740 milllion compared to Rs 472 million during Q3FY24, change 57%. Operating EBITDA: Rs 171 million compared to Rs 60 million during Q3FY24. EBITDA Margin: 23.1% for Q3FY25. ESOP cost: Rs 13 million compared to Rs 27 million during Q3FY24, change -52%. Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals said: “I am pleased with the Q3FY25 performance that is reflective of the strategic choices we have made. With revenues of Rs 740 million, a 57% growth YoY, and a 183% YoY increase in operating EBITDA (pre-ESOP) to Rs 171 million, our performance demonstrates an effective alignment of our operations with market opportunities. The sale of Faridabad facility for Rs 410 million has further strengthened our financial foundation. The cash position of Rs 1,321 million as of December 31, 2024, gives us the flexibility to invest in areas that promise sustainable growth. On a YTD basis, our 27% revenue growth to Rs 2102 million, coupled with a 53% rise in operating EBITDA to Rs 482 million with 390 bps margin expansion, highlights the success of our business discipline and seamless integration of acquired business. As we move forward, we shall continue to remain focused on organic growth supported by strategic inorganic initiatives leveraging our internal accruals to build a more resilient and dynamic organisation.” Result PDF
Pharmaceuticals company Jagsonpal Pharmaceuticals announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenues at Rs 747 million, reflecting a growth of 29.2%. Operating margins (pre-ESOP) expanded by 290 bps to 24.6% driving 46% YoY growth in operating EBITDA to Rs 184 million. Net profit increased YoY by 53% to Rs 114 million, reflecting a net profit margin of 15.3%. H1FY25 Financial Highlights: Revenues at Rs 1,361 million, reflecting a growth of 15.3%. Operating margins (pre-ESOP) expanded by 130 bps to 22.9% driving a 22.4% YoY growth in operating EBITDA to Rs 311 million. Net profit increased by 12% YoY to Rs 168 million, reflecting a net profit margin of 12.3%. Management Commentary: We are pleased to report a robust performance for Q2FY25 achieving revenue of Rs747 million, reflecting a remarkable 29.2% growth compared to Q2 FY24. This growth underscores success of our various strategic initiatives and the effective integration of the Yash Pharma business which we acquired in Q1FY25., with Q2FY25 marking first full quarter of contribution. Eight of our top ten brands are now on growth track and we are seeing some positive traction in our recent launches. Financially, we achieved an operating EBITDA of Rs184 million in Q2 FY25, reflecting a 46.0% YoY increase. Operating margins (pre-ESOP) expanded by 290 basis points to 24.6%. Our net profit rose 53% YoY to Rs114 million, yielding a net profit margin of 15.3%. In the first half of FY25, revenues totalled Rs1,361 million, YoY up by 15.3%, with operating margins expanding by 130 basis points to 22.9%. Our operating EBITDA for H1FY25 increased YoY by 22.4% to Rs311 million, reflecting an operating margin of 22.9%. We remain committed to delivering sustained, profitable growth and stay on course to our strategic direction as we progress through the year. Result PDF
Jagsonpal Pharmaceuticals announced Q2FY24 & H1FY24 results: Q2FY24: Revenues: Rs 57.8 crore, showing a decrease of 4.5% compared to Q2FY23. Operating EBITDA: Rs 12.6 crore. EBITDA Margin: 21.7%, an increase of 100 basis points (bps) from Q2FY23. ESOP Cost: Rs 4.2 crore. PAT (Profit After Tax): Rs 7.5 crore, marking a decrease of 27.9% compared to Q2FY23. H1FY24: Revenues: Rs 118.0 crore, showing a decrease of 2.6% compared to H1FY23. Operating EBITDA: Rs 25.4 crore, reflecting a 17.6% increase from H1FY23. EBITDA Margin: 21.5%, an increase of 360 bps from H1FY23. ESOP Cost: Rs 8.4 crore. PAT (Profit After Tax): Rs 15.0 crore, reflecting a 12.8% increase compared to H1FY23. Commenting on the Company’s performance, Manish Gupta, Managing Director stated, “We had a satisfactory outcome for the period, as the performance should be seen in the context of challenging external operating environment with slowing industry coupled with internal challenges in our flagship products - hyper-competition with 75+ competitors in Divatrone®(Dydrogesterone) and availability of counterfeits products in Indocap SR® (Indomethacin). Overall, we maintained our profitability for the quarter, with 100 bps improvement in operating margins, even as we reported a 4.5% decline in revenues. We maintained cash balance at Rs 125 crore despite dividend payout of Rs 13.1 crore during the quarter. We introduced certain structural initiatives including strengthening anti-counterfeit packing for our key brands. These, along with proposed new product launches gives us the confidence of returning to top-line growth from Q4FY24 onwards.” Result PDF